Amoy Diagnostics Balance Sheet Health
Financial Health criteria checks 5/6
Amoy Diagnostics has a total shareholder equity of CN¥1.8B and total debt of CN¥52.9M, which brings its debt-to-equity ratio to 2.9%. Its total assets and total liabilities are CN¥2.0B and CN¥227.1M respectively. Amoy Diagnostics's EBIT is CN¥326.0M making its interest coverage ratio -13.4. It has cash and short-term investments of CN¥1.1B.
Key information
2.9%
Debt to equity ratio
CN¥52.95m
Debt
| Interest coverage ratio | -13.4x |
| Cash | CN¥1.09b |
| Equity | CN¥1.81b |
| Total liabilities | CN¥227.13m |
| Total assets | CN¥2.04b |
Recent financial health updates
Amoy Diagnostics (SZSE:300685) Has A Rock Solid Balance Sheet
Dec 19
Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt
Apr 18Recent updates
Amoy Diagnostics (SZSE:300685) Has A Rock Solid Balance Sheet
Dec 19Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Earnings Haven't Escaped The Attention Of Investors
Sep 18Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?
Aug 23Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's
May 27Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%
Apr 24Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt
Apr 18What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You
Mar 02Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?
Mar 01Financial Position Analysis
Short Term Liabilities: 300685's short term assets (CN¥1.7B) exceed its short term liabilities (CN¥216.3M).
Long Term Liabilities: 300685's short term assets (CN¥1.7B) exceed its long term liabilities (CN¥10.8M).
Debt to Equity History and Analysis
Debt Level: 300685 has more cash than its total debt.
Reducing Debt: 300685's debt to equity ratio has increased from 0% to 2.9% over the past 5 years.
Debt Coverage: 300685's debt is well covered by operating cash flow (611.4%).
Interest Coverage: 300685 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 20:07 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amoy Diagnostics Co., Ltd. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yolanda Yin | China Galaxy International Securities (Hong Kong) |
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Jin Zhang | China International Capital Corporation Limited |